DOSAGE AND ADMINISTRATION:
For oral administration:
Adults: 50-100mg/dose given daily
Children: 1-2mg/dose given daily
Pulmonary edema, cardiogenic shock, bradycardia, heart block or uncompensated congestive heart failure.
1. Abrupt withdrawal of the drug should be avoided and the drug should be discontinued over 1-2 weeks.
2. Modify dosage in patients with renal impairment.
Bradycardia, hypotension, second or third degree A-V block, dizziness, fatigue, lethargy, headache; wheezing and dyspnea have occurred when daily dosage exceeded 100mg/day.
1. Catecholamine-depleting drugs (eg. Reserpine) may have an additive effect when given with beta-blocking agents. Patients treated with atenolol plus a catecholamine depletory should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.
2. Calcium channel blockers may also have an additive effect when given with atenolol.
3. Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beat blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.
4. Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin, may decrease the hypotensive effects of beta blockers.
Store in a dry place, below 25℃. Protect from direct sunlight.